Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 1/20 | 0.40 |
| ▸ | GBA1 | P04062 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13224040 | 1.00 | OPRL1 (0.40) | OPRL1GBA1MEN1KMT2A | |
| SCHEMBL13224067 | 0.91 | OPRL1 (0.37) | OPRL1 | |
| SCHEMBL31649403 | 0.79 | OPRL1 (0.41) | OPRL1 | |
| SCHEMBL14389977 | 0.78 | OPRL1 (0.40) | OPRL1 | |
| SCHEMBL11947613 | 0.78 | OPRL1 (0.40) | OPRL1 | |
| SCHEMBL5347104 | 0.78 | KDM4E (0.54) | OPRL1 | |
| SCHEMBL14120027 | 0.74 | OPRL1 (0.41) | OPRL1MEN1KMT2A | |
| SCHEMBL14120025 | 0.74 | OPRL1 (0.41) | OPRL1MEN1KMT2A | |
| SCHEMBL12734546 | 0.73 | CYP2D6 (0.41) | OPRL1 | |
| SCHEMBL12734441 | 0.73 | CYP2D6 (0.41) | OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7781418-B2 | enantiomerically pure (1R,6S)-2-Azabicyclo-[4.3.0]nonane-8,8-diphosphonic acid; osteoporosis, osteolytic bone metastasis, rheumatoid arthritis and osteoarthritis; enhanced inhibitory effect on farnesyl pyrophosphate synthase | ISIS INNOVATION LTD. (GB) | 2010-08-24 | — | — | US | claimed |
| EP-2089403-B1 | (1R,6S)-2-AZABICYCLO[4.3.0] NONANE-8,8-DIPHOSPHONIC ACID AND ITS USE IN TREATING OR PREVENTING BONE DISORDERS, FOR EXAMPLE, OSTEOPOROSIS OR PAGET'S DISEASE | ISIS INNOVATION (GB) | 2014-05-07 | — | — | EP | disclosed |
| EP-2089403-B1 | (1R,6S)-2-AZABICYCLO[4.3.0] NONANE-8,8-DIPHOSPHONIC ACID AND ITS USE IN TREATING OR PREVENTING BONE DISORDERS, FOR EXAMPLE, OSTEOPOROSIS OR PAGET'S DISEASE | ISIS INNOVATION (GB) | 2014-05-07 | — | — | EP | disclosed |
| US-7781418-B2 | enantiomerically pure (1R,6S)-2-Azabicyclo-[4.3.0]nonane-8,8-diphosphonic acid; osteoporosis, osteolytic bone metastasis, rheumatoid arthritis and osteoarthritis; enhanced inhibitory effect on farnesyl pyrophosphate synthase | ISIS INNOVATION LTD. (GB) | 2010-08-24 | — | — | US | disclosed |
| US-7781418-B2 | enantiomerically pure (1R,6S)-2-Azabicyclo-[4.3.0]nonane-8,8-diphosphonic acid; osteoporosis, osteolytic bone metastasis, rheumatoid arthritis and osteoarthritis; enhanced inhibitory effect on farnesyl pyrophosphate synthase | ISIS INNOVATION LTD. (GB) | 2010-08-24 | — | — | US | disclosed |
| US-7781418-B2 | enantiomerically pure (1R,6S)-2-Azabicyclo-[4.3.0]nonane-8,8-diphosphonic acid; osteoporosis, osteolytic bone metastasis, rheumatoid arthritis and osteoarthritis; enhanced inhibitory effect on farnesyl pyrophosphate synthase | ISIS INNOVATION LTD. (GB) | 2010-08-24 | — | — | US | disclosed |
| US-20090069272-A1 | Composition for treating bone disorders | THE PROCTER & GAMBLE COMPANY AND UNIVERSITY OF ROCHESTER (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090069272-A1 | Composition for treating bone disorders | THE PROCTER & GAMBLE COMPANY AND UNIVERSITY OF ROCHESTER (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090069272-A1 | Composition for treating bone disorders | THE PROCTER & GAMBLE COMPANY AND UNIVERSITY OF ROCHESTER (US) | 2009-03-12 | — | — | US | disclosed |
| WO-2008076417-A1 | (1R,6S)-2-AZABICYCLO[4.3.0] NONANE-8,8-DIPHOSPHONIC ACID AND ITS USE IN TREATING OR PREVENTING BONE DISORDERS, FOR EXAMPLE, OSTEOPOROSIS OR PAGET'S DISEASE | THE PROCTER & GAMBLE COMPANY (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069272-A1 | Composition for treating bone disorders | ACP3, SOST, COL2A1 | OPRL1 1287/4885GBA1 3252/4885MEN1 1705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.